author-photo

Sharad A. Ghamande

Georgia Regents University

104

Papers

1166

Citations

Citation Trend

Filter By

Papers (75) Sort By

Journal Conference Others

Tumor-intrinsic and -extrinsic (immune) gene signatures robustly predict overall survival and treatment response in high grade serous ovarian cancer patients.

2021 American Journal of Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.

2021 Cancer Gene Therapy
Show All
- Source
- Cite
- Save
Citations (1)
Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix.

2021 Obstetrics & Gynecology
Show All
- Source
- Cite
- Save
Citations (0)
Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

2021 Obstetrical & Gynecological Survey
Show All
- Source
- Cite
- Save
Citations (0)
Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A clinical calculator to personalize chemotherapy in early-stage clear cell ovarian cancer

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)